Gilead/J&J Collaboration Seeks To Create Triple-Therapy Successor To Atripla
This article was originally published in The Pink Sheet Daily
Executive Summary
The opportunity for J&J's investigative non-nucleoside reverse transcriptase inhibitor may come at the expense of BMS, Gilead's partner on Atripla.